A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Breast Reduction
Interventions
DRUG

Bupivacaine Hydrochloride

20 ml of 0.25% Bupivacaine (50 mg) with 20 ml of injectable saline (total of 40 cc) as a subcutaneous infiltration along the inframammary fold incision on one breast

DRUG

Liposomal Bupivacaine

20 ml of Liposomal (Exparel) Bupivacaine (266 mg/20 ml) on the contralateral breast

Trial Locations (1)

55905

Mayo Clinic Minnesota, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05891613 - A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction | Biotech Hunter | Biotech Hunter